GSK and Vir to join forces to research potential Covid-19 treatments
Experts have said it could take 12-months to develop a coronavirus vaccine
06 April 2020 - 16:35
Bengaluru — UK drugmaker GlaxoSmithKline will invest $250min Vir Biotechnology and collaborate to develop potential treatments for Covid-19, the disease caused by the new coronavirus, the companies said on Monday.
Vir's shares jumped 35% before the bell, while GSK was up about 1%...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.